Skip to content

Shattuck Labs, Inc. STTK Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Amgen logo
AmgenAMGN
-$959M-9.7%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-$3.03M+72.6%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$1.5M+12.1%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$23.69M-48.9%
MoonLake Immunotherapeutics logo
MoonLake ImmunotherapeuticsMLTX
$7.12M+558%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$2.33M+91.4%

Other financials

Income statement

See full
Revenue-
Operating income-$15.5M-8.0%
Net income-$14.8M-7.8%
EPS (diluted)-$0.13+51.9%

Balance sheet

See full
Cash & equivalents$90.4M+48.5%
Total debt$2.9M-9.5%
Total equity$95.8M+41.8%
Total assets$102.1M+32.3%

Cash flow

See full
Operating cash flow-$13.4M-11.6%
CapEx$63.0K
Free cash flow-$13.5M-12.1%

Valuation

See full
Market cap$564.45M+1,131%
Enterprise value$476.92M-4,119%
P/S564.5×+554×

Profitability

See full
Operating margin-5,266.4%-9,520pp
Net margin-4,987.4%-8,966pp
FCF margin-4,140.8%-7,144pp

Returns & leverage

See full
Return on equity-61%-8.0pp
Debt / equity0.0×
Current ratio22.1×+13.0×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: Shattuck Labs, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Shattuck Labs, Inc.'s change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Shattuck Labs, Inc.'s change in accrued liabilities?
Shattuck Labs, Inc. (STTK) reported change in accrued liabilities of -$1.96M in Q1 2026.
How has Shattuck Labs, Inc.'s change in accrued liabilities changed year-over-year?
Shattuck Labs, Inc.'s change in accrued liabilities decreased by 173.0% year-over-year, from -$716K to -$1.96M.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.